Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to Treat Mild to Moderate COVID-19 in India

Shots:

• Glenmark has received manufacturing and marketing approval for its antiviral drug FabiFlu (favipiravir) to treat COVID-19 in India. The drug will be available as a prescribed therapy for INR 103/tablet with recommended dose being 1800mg (bid) on day 1, followed by 800mg (bid) up to day 14
• Favipiravir demonstrated clinical improvements of up to 88% in SARS-CoV-2 virus infection, with rapid reduction in viral load by 4 days across the age groups 20 to >90yrs., including in patients with co-morbid conditions like diabetes and heart disease suffering from mild to moderate COVID-19
• The drug receives MHLW’s approval in 2014 to treat novel or re-emerging influenza virus infections. Additionally, the company has initiated clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India

Click here to read full press release/ article | Ref: Businesswire | Image: Bloomlive

Related News: Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India